Matthew Keller
Stock Analyst at HC Wainwright & Co.
(2.37)
# 2,602
Out of 4,981 analysts
6
Total ratings
50%
Success rate
14.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IFRX InflaRx | Assumes: Buy | $6 | $1.26 | +376.19% | 1 | Sep 2, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $18 | $7.83 | +129.89% | 1 | Aug 26, 2025 | |
| PHIO Phio Pharmaceuticals | Reiterates: Buy | $14 | $2.18 | +542.20% | 1 | Aug 15, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Buy | $6 | $5.37 | +11.73% | 1 | Aug 14, 2025 | |
| ACXP Acurx Pharmaceuticals | Maintains: Buy | $8 → $31 | $4.31 | +619.26% | 1 | Aug 12, 2025 | |
| FGEN FibroGen | Maintains: Buy | $10 → $43 | $12.03 | +257.44% | 1 | Aug 7, 2025 |
InflaRx
Sep 2, 2025
Assumes: Buy
Price Target: $6
Current: $1.26
Upside: +376.19%
Gyre Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $18
Current: $7.83
Upside: +129.89%
Phio Pharmaceuticals
Aug 15, 2025
Reiterates: Buy
Price Target: $14
Current: $2.18
Upside: +542.20%
Galectin Therapeutics
Aug 14, 2025
Reiterates: Buy
Price Target: $6
Current: $5.37
Upside: +11.73%
Acurx Pharmaceuticals
Aug 12, 2025
Maintains: Buy
Price Target: $8 → $31
Current: $4.31
Upside: +619.26%
FibroGen
Aug 7, 2025
Maintains: Buy
Price Target: $10 → $43
Current: $12.03
Upside: +257.44%